Stockscreener 앱 받기
0.8611
2.14%
-0.0189
전일 마감가:
$0.88
열려 있는:
$0.93
하루 거래량:
16,609
Relative Volume:
0.22
시가총액:
$10.19M
수익:
$248.40K
순이익/손실:
$-3.05M
주가수익비율:
-3.298
EPS:
-0.2611
순현금흐름:
$-3.30M
1주 성능:
-6.40%
1개월 성능:
+1.06%
6개월 성능:
-18.76%
1년 성능:
-54.68%
1일 변동 폭
$0.85
$0.93
1주일 범위
$0.7617
$0.93
52주 변동 폭
$0.6801
$3.68
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Compare GDTC vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
0.8611 | 10.64M | 248.40K | -3.05M | -3.30M | -0.2611 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomed Therapeutics Ltd 주식(GDTC)의 최신 뉴스
CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CytoMed Therapeutics Ltd SEC Filing (Aug 11, 2026) - Stock Titan
CytoMed Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
CytoMed Therapeutics Ltd (GDTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CytoMed Therapeutics Ltd (GDTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CytoMed Therapeutics Ltd (GDTC) Institutional Confidence - TradingKey
GDTC|CytoMed Therapeutics Ltd|Price:0.880|Chg%:-0.110 - TradingKey
CytoMed Therapeutics Ltd (GDTC) Cash Flow - TradingKey
CytoMed Therapeutics Ltd (GDTC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CytoMed Therapeutics Ltd (GDTC) Balance Sheet - TradingKey
CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CytoMed Therapeutics Ltd (GDTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CytoMed Therapeutics Ltd (GDTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GDTC|CytoMed Therapeutics Ltd|Price:0.990|Chg%:+0.140 - TradingKey
CytoMed Therapeutics Ltd (GDTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytoMed Therapeutics Ltd (GDTC) Income Statement - TradingKey
Form 13D/A CytoMed Therapeutics Ltd For: 24 July By Investing.com - Investing.com South Africa
CytoMed Therapeutics (GDTC) director adds 200,000 shares in July buys - Stock Titan
Form 4 CytoMed Therapeutics Ltd For: 24 July By Investing.com - Investing.com South Africa
CytoMed Therapeutics (GDTC) insider discloses two ordinary share dispositions - Stock Titan
CytoMed Therapeutics' US$1.7m Market Cap Fall Books Insider Losses - simplywall.st
CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector - FinancialContent
CytoMed Therapeutics(GDTC) Stock Options Chain | Quotes & News - Moomoo
CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
CytoMed Therapeutics (GDTC) Stock Forecast & Analyst Ratings - Moomoo
CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector - FinancialContent
GDTCCytoMed Therapeutics Ltd Options - Finviz
CytoMed, a Singapore Biotech, RevolutionizesCancer Treatment Using Donor Immune Cells - openPR.com
CytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBank - The Globe and Mail
Form 6K CytoMed Therapeutics Ltd For: 23 June - Investing.com UK
Form 6K CytoMed Therapeutics Ltd For: 23 June By Investing.com - Investing.com Australia
CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) shareholders approve all AGM proposals - Stock Titan
CytoMed Therapeutics (GDTC) Dips 2.48% as Key Support at $1.08 Comes into FocusDouble Top - newsline.com
CytoMed Therapeutics (NASDAQ: GDTC) director discloses holding 4,000 Ordinary Shares - Stock Titan
CytoMed Therapeutics LtdA Rising Star in Singapore's Cancer Biotechnology Sector - openPR.com
CytoMed Therapeutics Limited is accelerating its international expansion - openPR.com
CytoMed Therapeutics (NASDAQ: GDTC) director reports 2,469 ordinary shares on Form 3 - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director files initial Form 3 ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director Choo Chee Kong details direct and indirect share ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) CFO reports holding 25,781 ordinary shares - Stock Titan
CytoMed Therapeutics (GDTC) chair adds 112,000 shares in private purchase - Stock Titan
Cytomed Therapeutics Ltd (GDTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytomed Therapeutics Ltd 주식 (GDTC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Choo Chee Kong | Director |
May 13 '26 |
Buy |
1.15 |
112,000 |
128,778 |
430,324 |
0.86%
0.31%
자본화:
|
볼륨(24시간):